Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4–6 cycles). At interim analysis, progression-free survi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer cell 2023-06, Vol.41 (6), p.1061-1072.e4
Hauptverfasser:	Yang, Yunpeng, Pan, Jianji, Wang, Hui, Zhao, Yuanyuan, Qu, Shenhong, Chen, Nianyong, Chen, Xiaozhong, Sun, Yan, He, Xiaohui, Hu, Chaosu, Lin, Lizhu, Yu, Qitao, Wang, Siyang, Wang, Guihua, Lei, Feng, Wen, Jiyu, Yang, Kunyu, Lin, Zhixiong, Guo, Ye, Chen, Shaoqing, Huang, Xiaoming, Wu, Yanjie, Liang, Liang, Chen, Chenqi, Bai, Fan, Ma, Xiaopeng, Zhang, Yun, Leaw, Shiangjiin, Zhang, Li, Fang, Wenfeng
Format:	Artikel
Sprache:	eng
Schlagworte:	biomarker clinical trial double-blinded gene expression profiling immunotherapy nasopharyngeal carcinoma PD-1 inhibitor randomized tislelizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4–6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo-chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p
ISSN:	1535-6108 1878-3686
DOI:	10.1016/j.ccell.2023.04.014